Leiomodin-1 (LMOD1)

Leiomodin-1 (LMOD1) is a smooth muscle–selective actin-binding protein essential for organizing the actin cytoskeleton, specifically by nucleating and regulating thin filament assembly in contractile cells[1]. It is highly expressed in smooth muscle tissues such as major arteries, visceral organs of the gastrointestinal tract, and is under transcriptional control by serum response factor (SRF)/myocardin (MYOCD) signaling[1][2][5]. LMOD1 contributes to the assembly and stability of actin filaments by interacting with tropomyosin via a specialized N-terminal tropomyosin-binding domain[1]. Mutations in LMOD1 are associated with severe congenital intestinal motility disorders, notably megacystis–microcolon–intestinal hypoperistalsis syndrome (MMIHS3), as well as loss of contractility in smooth muscle, highlighting its indispensable role in muscle function and as a biomarker of smooth muscle cell integrity[2][4]. Studies show that LMOD1 also plays a key role in myogenic differentiation and skeletal muscle regeneration, interacting with proteins such as SIRT1 to modulate key transcriptional and regenerative pathways[3]. Loss or reduction of LMOD1 is implicated in altered smooth muscle contractility and disease states such as vascular pathologies[2][5][4]. Direct targeting by drugs has not been described, but its critical position within cytoskeletal machinery and disease markers makes it a potential future target for therapeutic intervention.

Other names

Leiomodin-1LMOD1SM-Lmod64kDD11DSM-LMODSMLMOD64 kDa autoantigen 1D64 kDa autoantigen 1D364 kDa autoantigen D1Leiomodin (muscle form)Smooth muscle leiomodinThyroid-associated ophthalmopathy autoantigenMMIHS3leiomodin-1 (smooth muscle)thyroid and eye muscle autoantigen D1 (64kD)